| Previous Close | 33.3200 |
| Open | 33.3800 |
| Bid | 33.0100 x 9800 |
| Ask | 33.0200 x 29700 |
| Day's Range | 33.0100 - 33.4800 |
| 52 Week Range | 29.8300 - 37.3900 |
| Volume | 15,226,040 |
| Avg. Volume | 20,314,514 |
| Market Cap | 197.48B |
| Beta | 1.07 |
| PE Ratio (TTM) | 27.85 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.82%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Market Realist•5 hours ago
Why Pfizer’s Sutent Could Witness a Modest Decline in 2017
In 2016, Pfizer’s (PFE) Sutent reported revenues of ~$1.1 billion, which represented a ~2% decline on a YoY (year-over-year) basis.
- Market Realist•7 hours ago
How Pfizer’s Vaccine Franchise Is Positioned in 2017
In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.
- Market Realist•8 hours ago
Why Xeljanz Could Boost Pfizer’s Revenue Growth
In 2016, Pfizer’s (PFE) Xeljanz reported revenues of ~$927 million, which reflected a ~77% growth YoY (year-over-year).
